CMS Guidance on COVID-19 Vaccine Administration Rates and Policies

Oct 30, 2020 | Kimberly Sharpe-Scott

On October 28, the Centers for Medicare and Medicaid Services (CMS) released a comprehensive plan to remove regulatory barriers and ensure consistent coverage and payment for the administration of an eventual COVID-19 vaccine. CMS released a set of toolkits for providers, states and insurers to help the health care system prepare to administer the vaccine once it is available. These resources are designed to increase the number of providers that can administer the vaccine, ensure adequate reimbursement for administering the vaccine in Medicare, while making it clear to private insurers and Medicaid programs their responsibility to cover the vaccine at no charge to beneficiaries. Additionally, to ensure broad access to the COVID-19 vaccine, CMS released an Interim Final Rule with Comment Period (IFC) that states that any vaccine that receives Food and Drug Administration (FDA) authorization, either through an Emergency Use Authorization (EUA) or licensed under a Biologics License Application (BLA), will be covered under Medicare as a preventive vaccine at no cost to beneficiaries. The IFC also implements provisions to ensure coverage of a COVID-19 vaccine by most private health insurance plans without cost sharing from both in and out-of-network providers during the course of the public health emergency (PHE).

The CMS toolkits for state Medicaid agencies, providers who will administer the vaccine, and health insurance plans address issues related to access, billing and payment, and coverage. Several key highlights include:

Increasing Access to Vaccines for Medicare & Medicaid Beneficiaries

The toolkits give health care providers not currently enrolled in Medicare the information needed to administer and bill vaccines to Medicare patients. CMS is working to increase the number of providers able to administer a COVID-19 vaccine to Medicare beneficiaries, and new providers are now able to enroll as a “Medicare mass immunizers” through an expedited 24-hour process. CMS is also making it easier for newly enrolled Medicare providers to also enroll in state Medicaid programs to support state administration of vaccines for Medicaid recipients.

Coverage

As a condition of receiving free COVID-19 vaccines from the federal government, providers will be prohibited from charging consumers for administration of the vaccine. The toolkits provide specific information for Medicare, Medicare Advantage, Medicaid, private plans, and uninsured individuals.

Billing and Payment

The toolkits address issues related to billing and payment. After a vaccine for COVID-19 is approved, CMS will identify the specific vaccine codes, by dose if necessary, and specific vaccine administration codes for each dose for Medicare payment.

Medicare Payment

CMS also released new Medicare payment rates for COVID-19 vaccine administration. The Medicare payment rates will be $28.39 to administer single-dose vaccines. For a COVID-19 vaccine requiring a series of two or more doses, the initial dose(s) administration payment rate will be $16.94, and $28.39 for the administration of the final dose in the series. These rates will be geographically adjusted and recognize the costs involved in administering the vaccine, including the additional resources involved with required public health reporting, conducting important outreach and patient education, and spending additional time with patients answering any questions they may have about the vaccine. Medicare beneficiaries, those in Original Medicare or enrolled in Medicare Advantage, will be able to get the vaccine at no cost. Additionally, CMS is encouraging state policymakers and other private insurance agencies to utilize the information on the Medicare reimbursement strategy to develop their vaccine administration payment plan in the Medicaid program, CHIP, the Basic Health Program (BHP), and private plans. Using the Medicare strategy as a model would allow states to match federal efforts in successfully administering the full vaccine to the most vulnerable populations.

For additional information and details, access the below CMS guidance and resources:


About Kimberly Sharpe-Scott

More posts by Kimberly Sharpe-Scott

Related Posts

Doctor 563428 640
  • COVID-19
  • Health in All Policies
  • Leadership
  • Workforce Development

Preparing Your Local Health Department for the Future

If the pandemic has taught us one thing, it is the importance of preparedness....

Jan 15, 2021 | Guest Author

Preparing Your Local Health Department for the Future

Covid
  • COVID-19
  • Immunization

Dosing intervals for COVID-19 mRNA Vaccine

On January 6, CDC revised Interim Clinical Considerations for Use of mRNA...

Jan 14, 2021 | Beth Hess

Dosing intervals for COVID-19 mRNA Vaccine

Needleexchange 0
  • HIV, STI, & Viral Hepatitis

Join NACCHO’s SSP Monitoring & Evaluation Advisory Group

The National Association of County and City Health Officials (NACCHO), in...

Jan 07, 2021 | Kat Kelley

Join NACCHO’s SSP Monitoring & Evaluation Advisory Group

Shareable Vaccines
  • Immunization
  • Infectious Disease

NACCHO Partners with Mediaplanet for Its Vaccines...

New campaign emphasizes keeping up-to-date with routine vaccines.

Jan 07, 2021 | Andrea Grenadier

NACCHO Partners with Mediaplanet for Its Vaccines...

Molecular surveillance stock
  • HIV, STI, & Viral Hepatitis

We are People, Not Clusters

In this American Journal of Bioethics publication, the concerns of current and...

Jan 06, 2021 | Shalesha Majors

We are People, Not Clusters

NCSH small
  • HIV, STI, & Viral Hepatitis

Sexual History Taking Pocket Cards

These pocket cards — one focusing on adults, one on adolescents, and one a...

Jan 06, 2021 | Julia Zigman

Sexual History Taking Pocket Cards

Denver PTC Logo
  • COVID-19
  • HIV, STI, & Viral Hepatitis

Resource: STI Care Options During COVID-19

This document, developed by Denver PTC, provides options for delivery of...

Jan 06, 2021 | Julia Zigman

Resource: STI Care Options During COVID-19

Syringe pile
  • HIV, STI, & Viral Hepatitis

Syringe Services Programs: A Technical Package of...

A new technical assistance resource is available for SSPs to help guide...

Jan 06, 2021 | Julia Zigman

Syringe Services Programs: A Technical Package of...

Advocates for Youth Logo RRR blue
  • Health Equity & Social Justice
  • HIV, STI, & Viral Hepatitis

Capacity-Building Opportunity: Queer & Gender Equity...

Advocates for Youth’s Queer and Gender Equity Project (QGEP) is accepting...

Jan 06, 2021 | Julia Zigman

Capacity-Building Opportunity: Queer & Gender Equity...

Back to Top